| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 31/05/2024 | 17:08 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NASDAQ:HRTX | Heron Therapeautics Inc |
| 29/05/2024 | 14:05 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:HRTX | Heron Therapeautics Inc |
| 29/05/2024 | 14:05 | PR Newswire (US) | Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN") | NASDAQ:HRTX | Heron Therapeautics Inc |
| 07/05/2024 | 14:05 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:HRTX | Heron Therapeautics Inc |
| 07/05/2024 | 14:00 | PR Newswire (US) | Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates | NASDAQ:HRTX | Heron Therapeautics Inc |
| 24/04/2024 | 14:00 | PR Newswire (US) | Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 | NASDAQ:HRTX | Heron Therapeautics Inc |
| 11/04/2024 | 22:05 | PR Newswire (US) | Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City | NASDAQ:HRTX | Heron Therapeautics Inc |
| 28/03/2024 | 21:05 | PR Newswire (US) | Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference | NASDAQ:HRTX | Heron Therapeautics Inc |
| 13/03/2024 | 21:25 | AllPennyStocks.com | Biotech Finds Mid-Week Success Following Q4 Earnings Release | NASDAQ:HRTX | Heron Therapeautics Inc |
| 12/03/2024 | 21:05 | PR Newswire (US) | Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates | NASDAQ:HRTX | Heron Therapeautics Inc |
| 12/03/2024 | 12:22 | IH Market News | Global Markets Await U.S. Inflation Report: Mixed Movements in Pre-Market Trading | NASDAQ:HRTX | Heron Therapeautics Inc |
| 28/02/2024 | 14:00 | PR Newswire (US) | Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024 | NASDAQ:HRTX | Heron Therapeautics Inc |
| 14/02/2024 | 22:37 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:HRTX | Heron Therapeautics Inc |
| 24/01/2024 | 15:25 | AllPennyStocks.com | Premarket Heats Up For Biotech Before Opening Bell | NASDAQ:HRTX | Heron Therapeautics Inc |
| 24/01/2024 | 02:00 | PR Newswire (US) | Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures | NASDAQ:HRTX | Heron Therapeautics Inc |
| 20/01/2024 | 03:05 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:HRTX | Heron Therapeautics Inc |
| 07/01/2024 | 23:00 | PR Newswire (US) | Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain | NASDAQ:HRTX | Heron Therapeautics Inc |
| 15/11/2023 | 18:25 | AllPennyStocks.com | Biotech Shares Up Sharply Following Quarterly Results | NASDAQ:HRTX | Heron Therapeautics Inc |
| 14/11/2023 | 22:05 | PR Newswire (US) | Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance | NASDAQ:HRTX | Heron Therapeautics Inc |
| 07/11/2023 | 22:05 | PR Newswire (US) | Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023 | NASDAQ:HRTX | Heron Therapeautics Inc |
| 23/08/2023 | 22:08 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:HRTX | Heron Therapeautics Inc |
| 14/08/2023 | 22:05 | PR Newswire (US) | Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates | NASDAQ:HRTX | Heron Therapeautics Inc |
| 07/08/2023 | 22:05 | PR Newswire (US) | Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023 | NASDAQ:HRTX | Heron Therapeautics Inc |
| 01/08/2023 | 19:56 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities | NASDAQ:HRTX | Heron Therapeautics Inc |
| 25/07/2023 | 22:15 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:HRTX | Heron Therapeautics Inc |
| 24/07/2023 | 15:02 | PR Newswire (US) | Heron Therapeutics Announces Cost Reduction Plan and Restructuring | NASDAQ:HRTX | Heron Therapeautics Inc |
| 24/07/2023 | 15:00 | PR Newswire (US) | Heron Therapeutics Announces $30 Million Private Placement Financing | NASDAQ:HRTX | Heron Therapeautics Inc |
| 30/06/2023 | 22:06 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:HRTX | Heron Therapeautics Inc |
| 23/06/2023 | 22:29 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:HRTX | Heron Therapeautics Inc |
| 23/06/2023 | 22:19 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:HRTX | Heron Therapeautics Inc |